Kyverna Therapeutics Shares Rise on Manufacturing Deal for Autoimmune Disease Treatment

Dow Jones

Jul 27

Shares of Kyverna Therapeutics rose after the company struck a commercial manufacturing and supply deal with ElevateBio for miv-cel, a patient-cell treatment in development for autoimmune diseases, including stiff person syndrome and generalized myasthenia gravis.

Shares were recently up about 6% at $7.83 in late morning trading. The stock is down about 18% over the past three months

The agreement covers U.S. commercial and global clinical supply of miv-cel. The late-stage clinical biopharmaceutical company said the deal provides flexible, scalable supply to support potential launches in stiff person syndrome and generalized myasthenia gravis.

The companies said their partnership has delivered a clinical manufacturing success rate of more than 98% for miv-cel.

Kyverna said it remains on track to complete its rolling BLA submission for stiff person syndrome in the fourth quarter. The company said miv‑cel could become the first FDA approved CAR T-cell therapy for an autoimmune disease and the first approved treatment for stiff person syndrome.

Write to Doc Louallen at Doc.Louallen@wsj.com

(END) Dow Jones Newswires

July 27, 2026 10:53 ET (14:53 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2654206046"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2654206046\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2654206046?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 22:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654206046","market":"sg","top_or_hot":-1,"title":"Kyverna Therapeutics Shares Rise on Manufacturing Deal for Autoimmune Disease Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/KYTX\">Kyverna Therapeutics</a> rose after the company struck a commercial manufacturing and supply deal with ElevateBio for miv-cel, a patient-cell treatment in development for autoimmune diseases, including stiff person syndrome and generalized myasthenia gravis. \n</p>\n<p>\n  Shares were recently up about 6% at $7.83 in late morning trading. The stock is down about 18% over the past three months \n</p>\n<p>\n  The agreement covers U.S. commercial and global clinical supply of miv-cel. The late-stage clinical biopharmaceutical company said the deal provides flexible, scalable supply to support potential launches in stiff person syndrome and generalized myasthenia gravis. \n</p>\n<p>\n  The companies said their partnership has delivered a clinical manufacturing success rate of more than 98% for miv-cel. \n</p>\n<p>\n  Kyverna said it remains on track to complete its rolling BLA submission for stiff person syndrome in the fourth quarter. The company said miv‑cel could become the first FDA approved CAR T-cell therapy for an autoimmune disease and the first approved treatment for stiff person syndrome. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 27, 2026 10:53 ET (14:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kyverna Therapeutics Shares Rise on Manufacturing Deal for Autoimmune Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKyverna Therapeutics Shares Rise on Manufacturing Deal for Autoimmune Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-27 22:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/KYTX\">Kyverna Therapeutics</a> rose after the company struck a commercial manufacturing and supply deal with ElevateBio for miv-cel, a patient-cell treatment in development for autoimmune diseases, including stiff person syndrome and generalized myasthenia gravis. \n</p>\n<p>\n  Shares were recently up about 6% at $7.83 in late morning trading. The stock is down about 18% over the past three months \n</p>\n<p>\n  The agreement covers U.S. commercial and global clinical supply of miv-cel. The late-stage clinical biopharmaceutical company said the deal provides flexible, scalable supply to support potential launches in stiff person syndrome and generalized myasthenia gravis. \n</p>\n<p>\n  The companies said their partnership has delivered a clinical manufacturing success rate of more than 98% for miv-cel. \n</p>\n<p>\n  Kyverna said it remains on track to complete its rolling BLA submission for stiff person syndrome in the fourth quarter. The company said miv‑cel could become the first FDA approved CAR T-cell therapy for an autoimmune disease and the first approved treatment for stiff person syndrome. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 27, 2026 10:53 ET (14:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KYTX","symbol_name":"Kyverna Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2654206046","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654206046","pubTimestamp":1785163980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Kyverna Therapeutics rose after the company struck a commercial manufacturing and supply deal with ElevateBio for miv-cel, a patient-cell treatment in development for autoimmune diseases, including stiff person syndrome and generalized myasthenia gravis.Shares were recently up about 6% at $7.83 in late morning trading. The stock is down about 18% over the past three monthsThe agreement covers U.S. commercial and global clinical supply of miv-cel. The late-stage clinical biopharmaceutical company said the deal provides flexible, scalable supply to support potential launches in stiff person syndrome and generalized myasthenia gravis.The companies said their partnership has delivered a clinical manufacturing success rate of more than 98% for miv-cel.Kyverna said it remains on track to complete its rolling BLA submission for stiff person syndrome in the fourth quarter. The company said mivcel could become the first FDA approved CAR T-cell therapy for an autoimmune disease and the","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KYTX":"Kyverna Therapeutics","BK4139":"生物科技"},"translate_title":"Kyverna Therapeutics 股价因自身免疫性疾病治疗制造交易而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYTX":1.5},"content_text":"Shares of Kyverna Therapeutics rose after the company struck a commercial manufacturing and supply deal with ElevateBio for miv-cel, a patient-cell treatment in development for autoimmune diseases, including stiff person syndrome and generalized myasthenia gravis. \n\n\n  Shares were recently up about 6% at $7.83 in late morning trading. The stock is down about 18% over the past three months \n\n\n  The agreement covers U.S. commercial and global clinical supply of miv-cel. The late-stage clinical biopharmaceutical company said the deal provides flexible, scalable supply to support potential launches in stiff person syndrome and generalized myasthenia gravis. \n\n\n  The companies said their partnership has delivered a clinical manufacturing success rate of more than 98% for miv-cel. \n\n\n  Kyverna said it remains on track to complete its rolling BLA submission for stiff person syndrome in the fourth quarter. The company said miv‑cel could become the first FDA approved CAR T-cell therapy for an autoimmune disease and the first approved treatment for stiff person syndrome. \n\n\n \n\n\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 27, 2026 10:53 ET (14:53 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}